Fifth Third Bancorp Boosts Holdings in United Therapeutics Corporation $UTHR

Fifth Third Bancorp increased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 35,842.9% during the 1st quarter, Holdings Channel.com reports. The fund owned 164,978 shares of the biotechnology company’s stock after purchasing an additional 164,519 shares during the quarter. Fifth Third Bancorp’s holdings in United Therapeutics were worth $97,829,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Avoro Capital Advisors LLC grew its holdings in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the period. Janus Henderson Group PLC grew its stake in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the last quarter. Finally, Darwin Global Management Ltd. purchased a new position in United Therapeutics during the 3rd quarter worth approximately $317,617,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on UTHR shares. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $644.82.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,851,434.88. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold 603,543 shares of company stock worth $339,592,598 in the last quarter. Insiders own 8.60% of the company’s stock.

United Therapeutics Trading Down 1.0%

Shares of United Therapeutics stock traded down $5.42 during trading hours on Friday, hitting $547.06. 301,306 shares of the company were exchanged, compared to its average volume of 526,796. The business has a 50-day moving average of $556.70 and a 200-day moving average of $529.44. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The stock has a market capitalization of $23.22 billion, a price-to-earnings ratio of 20.19, a P/E/G ratio of 1.80 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.63 earnings per share. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.